| 摘要 |
<p>The present invention concerns a pharmaceutical product, eg a vaccine composition or vaccine kit, which comprises HpaA and Hpa44 polypeptides. The invention also concerns a fusion polypeptide comprising both HpaA and Hpa44 amino acid sequences, as well as a nucleic acid encoding such a fusion polypeptide. In addition, the invention concerns a pharmaceutical product comprising separate nucleotide sequences respectively encoding HpaA and Hpa44 polypeptides. HpaA together with Hpa44 provides a synergistic combination that can be used to treat and/or reduce the risk of Helicobacter pylori infection in a mammal.</p> |
